A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device in Adult Participants for the Appearance of Cellulite

NCT05730335 | Completed Phase 4 Results FDA Device

• 1 other identifier: M24-262
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 4

Brief Summary

Cellulite is the rippling or dimpling of the skin most commonly located on the thighs and buttocks of women. Its appearance and texture are often likened to that of "cottage cheese" or an orange peel. Rapid Acoustic Pulse (RAP) is an electrohydraulic (EH) device developed to improve the appearance of cellulite through microscopic disruption of the connection between the skin and underlying tissue leading to a reduction in the severity of dimples and ridges. The purpose of this study is to assess adverse events and effectiveness of RAP in adults seeking treatment of cellulite. RAP is an FDA approved device for the long-term improvement in the appearance of cellulite in the buttocks and thighs. Participants 18-50 years of age seeking treatment of cellulite will be enrolled. Up to 60 participants will be enrolled in the study at 4 sites in the United States. Participants will receive 2 separate cellulite treatment sessions. Each treatment session will consist of RAP treatment delivered to bilateral thigh and/or buttock areas using the same treatment settings for both sides. The study duration is up to 60 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Conditions

Cellulite

Keywords

Cellulite; Rapid Acoustic Pulse; RAP

Outcome Measures

Primary Outcomes (1)

• Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel

  Photographs of the treatment areas were taken at baseline, and at 12-weeks after the first treatment to determine if the RAP treatment had the effect of improvement in the appearance of cellulite. The photographs were assessed by blinded independent reviewers (IPR) to correctly identify the 12-weeks post-treatment photographs from randomly placed side-by-side comparison of before and after photographs. Reported here is the percentage (%) of images that were correctly identified by at least 2 out of 3 blinded independent reviewers.

  Baseline, Week 12

Secondary Outcomes (2)

• Number of Participants With "Agree" or "Strongly Agree" Responses to the Participant Satisfaction Survey in the Improvement in Appearance of Cellulite

  Baseline, Week 12

• Number of Participants With Device-related or Treatment-related: Adverse Events (AEs), Serious AEs (SAEs), Adverse Device Events (ADEs), Serious ADEs (SADEs), Unanticipated AEs or Unanticipated ADEs

  Week 1 up to Week 12

Study Arms (1)

Rapid Acoustic Pulse (RAP)

EXPERIMENTAL

Participants will receive 2 separate RAP cellulite treatments sessions.

Device: Rapid Acoustic Pulse

Interventions

Rapid Acoustic Pulse DEVICE

Transdermal Rapid Acoustic Pulse Treatments

Also known as: RAP

Rapid Acoustic Pulse (RAP)

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participants seeking treatment of cellulite in the thigh and/or buttock areas.
• Areas of moderate to severe cellulite on bilateral thigh and/or buttock using the Cellulite Dimple - At Rest Scale at Baseline with grades of 2 or 3 based on review of photos taken under the same lightening conditions planned for the trial.
• Participant will not have had invasive or energy-based cellulite (liposuction, subcision, RF, laser, ESWT, cryo-lipolysis, muscle stimulation, etc.) treatments in the treatment areas in the prior 12 months.
• Participant will not have used topical based cellulite treatments for prior 3 months and will not use during the trial
• Participant will not have used spray-on tanning treatments for 3 months prior to or during the term of the trial.

You may not qualify if:

• Metal or plastic implants (vascular stent, or implants in the hips, knees, etc.) in the treatment areas.
• Active electronic implants such as pacemakers, defibrillators
• History of coagulopathy and/or on anticoagulant medication
• Skin disorders (skin infections or rashes, psoriasis, etc.) in the treatment areas.
• Medical disorder that would hinder wound healing or immune response.
• Any surgical procedure in the treatment areas in the prior 3 months or planned during the duration of the study.
• Any other condition/disease/situation which, as deemed by the PI, would preclude participant from safely participating in or completing the study visits or that may confound study results.

Sponsors & Collaborators

• Zeltiq Aesthetics: lead

Study Sites (4)

Chicago Cosmetic Surgery and Dermatology

Chicago, Illinois, 60654, United States

Location

Skin and Laser Surgery Center of New England

Nashua, New Hampshire, 03060, United States

Location

Union Derm

New York, New York, 10003, United States

Location

Bellaire Dermatology

Bellaire, Texas, 77401, United States

Location

MeSH Terms

Conditions

Cellulite

Condition Hierarchy (Ancestors)

Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Global Medical Services
• Organization: AbbVie

abbvieclinicaltrials@abbvie.com

800-633-9110

Study Officials

• Zeltiq Aesthetics

  Zeltiq Aesthetics

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2023
• First Posted: February 15, 2023
• Study Start: February 7, 2023
• Primary Completion: November 3, 2023
• Study Completion: July 17, 2024
• Last Updated: June 24, 2025
• Results First Posted: December 27, 2024

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (4)